Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
156.00
+0.57 (0.37%)
Nov 20, 2024, 4:00 PM EST - Market closed
Biogen Revenue
Biogen had revenue of $2.47B in the quarter ending September 30, 2024, a decrease of -2.55%. This brings the company's revenue in the last twelve months to $9.61B, down -3.86% year-over-year. In the year 2023, Biogen had annual revenue of $9.84B, down -3.32%.
Revenue (ttm)
$9.61B
Revenue Growth
-3.86%
P/S Ratio
2.36
Revenue / Employee
$1,269,155
Employees
7,570
Market Cap
22.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | 14.38B | 925.00M | 6.88% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cardinal Health | 224.45B |
| Centene | 146.20B |
| Koninklijke Philips | 20.12B |
| Zimmer Biomet Holdings | 7.60B |
| STERIS | 5.33B |
| Illumina | 4.39B |
| Mettler-Toledo International | 3.76B |
| BioNTech SE | 3.39B |
BIIB News
- 19 hours ago - Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside - Benzinga
- 2 days ago - Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity - GlobeNewsWire
- 2 days ago - Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 - Benzinga
- 3 days ago - Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ - GlobeNewsWire
- 6 days ago - 5 Healthcare Stocks to Buy in a Beaten-Up Sector - Barrons
- 6 days ago - Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drug - Market Watch
- 6 days ago - EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen - Reuters
- 20 days ago - Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter - Seeking Alpha